David T. Weaver

12.4k total citations · 1 hit paper
150 papers, 9.0k citations indexed

About

David T. Weaver is a scholar working on Molecular Biology, Oncology and Genetics. According to data from OpenAlex, David T. Weaver has authored 150 papers receiving a total of 9.0k indexed citations (citations by other indexed papers that have themselves been cited), including 85 papers in Molecular Biology, 39 papers in Oncology and 29 papers in Genetics. Recurrent topics in David T. Weaver's work include DNA Repair Mechanisms (40 papers), Chronic Lymphocytic Leukemia Research (24 papers) and Cancer-related Molecular Pathways (14 papers). David T. Weaver is often cited by papers focused on DNA Repair Mechanisms (40 papers), Chronic Lymphocytic Leukemia Research (24 papers) and Cancer-related Molecular Pathways (14 papers). David T. Weaver collaborates with scholars based in United States, China and United Kingdom. David T. Weaver's co-authors include G. Todd Milne, Shengfang Jin, Melvin L. DePamphilis, Jonathan A. Pachter, Eric A. Hendrickson, György Hajnóczky, Irina M. Shapiro, David Baltimore, Xingguo Liu and Nikolai V. Boubnov and has published in prestigious journals such as Nature, Science and Cell.

In The Last Decade

David T. Weaver

149 papers receiving 8.9k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Targeting focal adhesion kinase renders pancreatic cancers responsive to checkpoint immunotherapy

2016 754 citations Irina M. Shapiro, David T. Weaver et al. profile →

Peers

Countries citing papers authored by David T. Weaver

Since Specialization

Citations

This map shows the geographic impact of David T. Weaver's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by David T. Weaver with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites David T. Weaver more than expected).

Fields of papers citing papers by David T. Weaver

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by David T. Weaver. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by David T. Weaver. The network helps show where David T. Weaver may publish in the future.

Co-authorship network of co-authors of David T. Weaver

This figure shows the co-authorship network connecting the top 25 collaborators of David T. Weaver. A scholar is included among the top collaborators of David T. Weaver based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with David T. Weaver. David T. Weaver is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Roles of PI3Kγ and PI3Kδ in mantle cell lymphoma proliferation and migration contributing to efficacy of the PI3Kγ/δ inhibitor duvelisib 2023 ·Scientific Reports ·Kathleen J. Till, (unknown), (unknown), (unknown), Thomas A. Marks, Sílvia Coma, David T. Weaver, Jonathan A. Pachter, Andrew R. Pettitt, Joseph R. Slupsky	5
2	Duvelisib Eliminates CLL B Cells, Impairs CLL-Supporting Cells, and Overcomes Ibrutinib Resistance in a Xenograft Model 2023 ·Clinical Cancer Research ·Shih‐Shih Chen, Jacqueline C. Barrientos, Gerardo Ferrer, (unknown), (unknown), (unknown), Michael Ibrahim, (unknown), (unknown), Jeffery L. Kutok, (unknown), (unknown), David T. Weaver, Jonathan A. Pachter, R. Kanti, Nicholas Chiorazzi	5
3	Capture at the ER-mitochondrial contacts licenses IP3 receptors to stimulate local Ca2+ transfer and oxidative metabolism 2022 ·Nature Communications ·Máté Katona, Ádám Bartók, Zuzana Nichtová, György Csordás, Elena Berezhnaya, David T. Weaver, (unknown), Péter Várnai, David I. Yule, György Hajnóczky	57
4	FAK inhibition alone or in combination with adjuvant therapies reduces cancer stem cell activity 2021 ·npj Breast Cancer ·S Timbrell, (unknown), Angela Cramer, (unknown), David T. Weaver, Jonathan A. Pachter, (unknown), Robert B. Clarke, Gillian Farnie, Nigel Bundred	22
5	Efficacy and Safety of Duvelisib Following Disease Progression on Ofatumumab in Patients with Relapsed/Refractory CLL or SLL in the DUO Crossover Extension Study 2020 ·Clinical Cancer Research ·Matthew S. Davids, Bryone J. Kuss, Peter Hillmen, Marco Montillo, Carol Moreno, James Essell, Nicole Lamanna, Zsolt Nagy, Constantine S. Tam, Stephan Stilgenbauer, Paolo Ghia, Julio Delgado, Stephanie Lustgarten, David T. Weaver, Hagop Youssoufian, Ulrich Jäger	33
6	Combinatorial Inhibition of Focal Adhesion Kinase and BCL-2 Enhances Antileukemia Activity of Venetoclax in Acute Myeloid Leukemia 2020 ·Molecular Cancer Therapeutics ·Xiangmeng Wang, Po Yee Mak, Hong Mu, Wenjing Tao, Arvind Rao, Visweswaran Ravikumar, Vivian Ruvolo, Jonathan A. Pachter, David T. Weaver, Michael Andreeff, Bing Xu, Bing Z. Carter	13
7	Effect of dose modifications on response to duvelisib in patients with relapsed or refractory chronic lymphocytic leukemia/small lymphocytic lymphoma in the DUO trial 2019 ·American Journal of Hematology ·Nicole Lamanna, (unknown), Árpád Illés, Gabriel Étienne, Julio Delgado, Bryone J. Kuss, Constantine S. Tam, Fritz Offner, Francesc Bosch, Matthew S. Davids, Ulrich Jaeger, Paolo Ghia, (unknown), David T. Weaver, Stephanie Lustgarten, Hagop Youssoufian, Stephan Stilgenbauer, Ian W. Flinn	1
8	Focal Adhesion Kinase as a Potential Target in AML and MDS 2017 ·Molecular Cancer Therapeutics ·Bing Z. Carter, Po Yee Mak, Xiangmeng Wang, Hui Yang, Guillermo Garcia‐Manero, Duncan H. Mak, Hong Mu, Vivian Ruvolo, Yihua Qiu, Kevin R. Coombes, Nianxiang Zhang, Brittany Knick Ragon, David T. Weaver, Jonathan A. Pachter, Steven M. Kornblau, Michael Andreeff	31
9	Activity of the PI3K-δ,γ inhibitor duvelisib in a phase 1 trial and preclinical models of T-cell lymphoma 2017 ·Blood ·Steven M. Horwitz, Raphael Koch, Pierluigi Porcu, Yasuhiro Oki, Alison J. Moskowitz, Megan N. Perez, Patricia L. Myskowski, Adam Officer, Jacob D. Jaffe, Sara Morrow, Kerstin Allen, Mark Douglas, Howard M. Stern, Jennifer Sweeney, Patrick Kelly, Virginia Kelly, Jon C. Aster, David T. Weaver, Francine M. Foss, David M. Weinstock	204
10	PI3K/mTOR Dual Inhibitor VS-5584 Preferentially Targets Cancer Stem Cells 2014 ·Cancer Research ·Vihren N. Kolev, Quentin G. Wright, Christian M. Vidal, Jennifer E. Ring, Irina M. Shapiro, Jill M. Ricono, David T. Weaver, Mahesh V. Padval, Jonathan A. Pachter, Qunli Xu	116
11	Loss of Miro1-directed mitochondrial movement results in a novel murine model for neuron disease 2014 ·Proceedings of the National Academy of Sciences ·Tammy Nguyen, Sang Su Oh, David T. Weaver, Agnieszka Lewandowska, (unknown), Max-Hinderk Schuler, Nathan K. Smith, Jane L. Macfarlane, Gerald W. Saunders, Cheryl A. Palmer, Valentina Debattisti, Takumi Koshiba, Stefan M. Pulst, Eva L. Feldman, György Hajnóczky, Janet M. Shaw	171
12	Overabundant FANCD2, alone and combined with NQO1, is a sensitive marker of adverse prognosis in breast cancer 2013 ·Annals of Oncology ·Rainer Fagerholm, Kam Sprott, Tuomas Heikkinen, Jiřina Bártková, Päivi Heikkilä, Kristiina Aittomäki, Jiří Bártek, David T. Weaver, Carl Blomqvist, Heli Nevanlinna	27
13	XPF Expression Correlates with Clinical Outcome in Squamous Cell Carcinoma of the Head and Neck 2011 ·Clinical Cancer Research ·Alec Vaezi, (unknown), Shama Buch, William E. Gooding, Lin Wang, Raja R. Seethala, David T. Weaver, Alan D. D’Andrea, Athanassios Argiris, Marjorie Romkes, Laura J. Niedernhofer, Jennifer R. Grandis	42
14	DNA Repair Protein Biomarkers Associated with Time to Recurrence in Triple-Negative Breast Cancer 2010 ·Clinical Cancer Research ·Brian M. Alexander, Kam Sprott, (unknown), XiaoZhe Wang, Alan D. D’Andrea, Stuart J. Schnitt, Laura C. Collins, David T. Weaver, Judy E. Garber	27
15	(S,E)-N-[1-(3-Heteroarylphenyl)ethyl]-3-(2-fluorophenyl)acrylamides: synthesis and KCNQ2 potassium channel opener activity 2004 ·Bioorganic & Medicinal Chemistry Letters ·Alexandre L’Heureux, Alain Martel, Huan He, Jie Chen, Li‐Qiang Sun, John E. Starrett, (unknown), Steven I. Dworetzky, Ronald J. Knox, David Harden, David T. Weaver, Mark Thompson, Yong‐Jin Wu	6
16	Rescue of a telomere length defect of Nijmegen breakage syndrome cells requires NBS and telomerase catalytic subunit 2001 ·Current Biology ·Velvizhi Ranganathan, Walter Heine, David Ciccone, K. Lenhard Rudolph, Xiaohua Wu, Sandy Chang, Mingqiu Hu, Ian M. Ahearn, David M. Livingston, Igor Resnick, Fred S. Rosen, E Seemanová, Petr Jarolı́m, Ronald A. DePinho, David T. Weaver	94
17	Inactivation of DNA-Dependent Protein Kinase by Protein Kinase Cδ: Implications for Apoptosis 1998 ·Molecular and Cellular Biology ·Ajit Bharti, Stine‐Kathrein Kraeft, Mrinal M. Gounder, Pramod S. Pandey, Shengfang Jin, Zhi-Min Yuan, Susan P. Lees‐Miller, Ralph R. Weichselbaum, David T. Weaver, Lan Bo Chen, Donald Küfe, Surender Kharbanda	188
18	V(D)J Recombination and Double-Strand Break Repair 1995 ·Advances in immunology ·David T. Weaver	51
19	seid Cells Efficiently Integrate Hairpin and Linear DNA Substrates 1994 ·Molecular and Cellular Biology ·Jane Staunton, David T. Weaver	17
20	Strand Breaks without DNA Rearrangement in V(D)J Recombination 1991 ·Molecular and Cellular Biology ·Eric A. Hendrickson, (unknown), David T. Weaver	9

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact